Tenmile
VC Fund
Perth, Australia
Tenmile is a VC fund in Perth focused on Health Care and Biotechnology. Tenmile invest quickly and confidently because it lacks the constraints that most venture capital funds.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Tenmile invests in
Stages Tenmile invests in
Countries Tenmile invests in
Round sizes
Round size
- Seed
- $2.5M–$8M
- Series A
- $3M–$177M
- Venture - Series Unknown
- $7.5M–$90M
Investment Focus
Industry
- Health Care 9 (43%)
- Biotechnology 9 (43%)
- Manufacturing 4 (19%)
- Pharmaceutical 3 (14%)
- Medical 2 (10%)
Stage
- Venture - Series Unknown 7 (33%)
- Series A 4 (19%)
- Seed 3 (14%)
- Series B 2 (10%)
- Series C 1 (5%)
Country
- Australia 10 (48%)
- United States 7 (33%)
- Canada 1 (5%)
- Switzerland 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kantoko is a dedicated Australian mental health platform that provides online ADHD assessment, diagnosis, and long-term care for adults. | $2.5M / Seed / Aug 13, 2026 | ||
| AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | ||
| Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders. | $90M / Venture - Series Unknown / May 27, 2025 | ||
| Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with significant unmet medical needs. Founded as a spin-out from Scorpion Therapeutics, it leverages proprietary drug discovery capabilities and arobust preclinical pipeline to advance multiple programs, primarily in precision oncology. | $177M / Series A / May 15, 2025 | ||
| AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M / Series C / Feb 03, 2025 | ||
| Proton Intelligence provides biomarker monitoring to manage chronic disease and save lives. The first biomarker is potassium, targeting hyperkalemia in chronic kidney disease (CKD) patients who have additional co-morbidities ProtonIntel was founded in 2020 and was headquartered in Vancouver, Canada. | $7M / Seed / Dec 24, 2024 | ||
| Xylo Bio is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications. | $8M / Seed / Jun 02, 2024 | ||
| Stamford Pharmaceuticals delivers biologicals, small molecule immune modulators, and chemotherapeutics to treat cancer patients. | Series A / Apr 10, 2024 | ||
| LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $3M / Series A / Feb 01, 2024 | ||
| Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. | Series B / Jan 05, 2024 | ||
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tenmile invest in?
Tenmile invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Venture - Series Unknown and Series A stage. Most of the 21 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Tenmile's check size?
Tenmile typically joins rounds of $2.5M–$8M at Seed, $3M–$177M at Series A and $7.5M–$90M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tenmile participates in.
When did Tenmile last invest?
The most recent investment recorded for Tenmile closed in Aug 2026. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
